In a major stride forward for Reviva Pharmaceuticals Holdings, the company’s stock has witnessed a significant surge subsequent to the release of promising topline results from its pivotal Phase 3 RECOVER trial. This trial scrutinized the efficacy of brilaroxazine, a serotonin-dopamine signaling modulator, in adult patients grappling with schizophrenia.
At the time of this publication, Reviva Pharmaceuticals Holdings, Inc stock (RVPH) has witnessed a surge.
Reviva Pharmaceuticals Holdings, Inc
Current Price: $5.88
Change : +2.13
Change (%): (56.77%)
Volume: 31.3M
Source: Tomorrow Events Market Data
The trial demonstrated resounding success, meeting its primary endpoint. Brilaroxazine, administered at the 50 mg dosage, exhibited a noteworthy and clinically substantial 10.1-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score in contrast to the placebo (-23.9 for brilaroxazine 50 mg versus -13.8 for placebo) at the conclusion of the fourth week.
According to analysis provided by Roth Capital Partners, the data showcases robustness across an array of endpoints, encompassing Positive Symptoms, Negative Symptoms, PANSS Social Cognition, PANSS Excitement/Agitation, Personal and Social Performance, as well as CGI-S Score. Analyst Scott Henry has expressed optimism over the discernible dose-response advantage of the 50mg brilaroxazine over the 15mg dosage. While the 15mg dose reveals clinical benefit on the lower spectrum, a 30mg dose in the forthcoming pivotal trial confirmation could potentially yield further market advantages.
Maintaining its Buy rating, Roth Capital Partners has set a price target of $12.
Roth Capital Partners additionally highlights a modestly elevated weight gain, surpassing initial projections. Patients receiving 50mg brilaroxazine experienced a 5.9% increase in weight, as opposed to the 2.9% noted in the placebo group. This discrepancy is expected to attract heightened attention in the forthcoming open-label extension (OLE) study, aiming to ascertain the duration and magnitude of this effect. The 15mg brilaroxazine dosage, in contrast, saw a more conservative 2.1% increase in weight, falling below the placebo threshold. Notably, no significant disparities were observed in LDL/HDL levels, with numerical favorability observed for brilaroxazine.
Reviva Pharmaceuticals Holdings’s brilaroxazine Phase 3 trial results have ushered in a wave of optimism among stakeholders, underscoring the potential for a groundbreaking treatment in the realm of schizophrenia therapeutics. With the data signaling not only statistical significance but also clinical efficacy, the company is poised to forge ahead in its pursuit of a transformative psychiatric intervention. Investors and industry experts alike are closely monitoring the trajectory of this development, as it stands to make a substantial impact on the landscape of mental health treatment.
